Table 3.
Association between anti-phospholipid syndrome* (APS), serologic abnormalities and inhibition of annexin V binding
| APS present (n = 29) | APS absent (n = 30) | P | Odds ratio (95% confidence intervals) | |
|---|---|---|---|---|
| IgG aCL† | 10·0 (0–17·6) | 5·0 (0–16·1) | 0·03 | 4·17 (1·15–15·04) |
| IgG anti-β2-GPI | 4·5 (0–11·3) | 0·9 (0–9·7) | 0·02 | 3·28 (1·13–9·54) |
| IgG anti-PT | 0·7 (0–78·5) | 4·4 (0–84·0) | 0·61 | 0·62 (0·22–1·73) |
| IgM aCL | 5·6 (0·4–76·2) | 3·8 (0–63·6) | 0·47 | 0·95 (0·31–2·89) |
| IgM anti-β2-GPI | 3·6 (0–46·9) | 2·2 (0–43·8) | 0·59 | 1·64 (0·58–4·62) |
| IgM anti-PT | 1·5 (0–9·2) | 0·8 (0–9·1) | 0·62 | 0·92 (0·32–2·61) |
| IgA aCL | 1·4 (0–30·3) | 1·2 (0–24·6) | 0·96 | 0·92 (0·33–2·59) |
| IgA anti-β2-GPI | 10·3 (0–239·2) | 7·9 (0–110·4) | 0·87 | 0·69 (0·23–2·11) |
| IgA anti-PT | 1·3 (0–9·5) | 2·1 (0–11·0) | 0·22 | 0·38 (0·13–1·13) |
| LA | 1·7 (1–2·8) | 1·5 (0·9–2·7) | 0·20 | 2·78 (0·64–12·10) |
| Annexin V inhibition | −3·4 (−11·4–0·6) | −1·1 (−10·8–1·2) | 0·22 | 2·85 (0·99–8·21) |
*
APS, Anti-phospholipid syndrome characterized clinically by either venous thrombosis, arterial thrombosis or recurrent (≥ 2) fetal loss.
†
All values (median (range)) are Z scores with the exception of lupus anti-coagulant (LA) activity, which is expressed as a ratio.
PT, Prothrombin.